Additional file 1: of Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway

Table S1. CDDP sensitivity assay of tissue samples from lung cancer patients (please refer to Additional file 2: Table S2 for patients’ characteristics). (DOCX 17 kb

Additional file 2: of Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway

Table S2. Pathological characteristics of patients. (DOCX 14 kb

Additional file 3: of Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway

Figure S1. Prolonged, escalating CDDP treatment enriched CDDP-resistant H460R and A549R NSCLC cells. MTT assay demonstrated that H460R and A549R cells with a significantly higher IC50 values against CDDP treatment. (DOCX 19 kb

Additional file 1: of Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor

Table S1. Primary antibodies used (DOC 28 kb

Additional file 3: of Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor

Figure S2. The uncoupling effect of JARID1B on NSCLC cell cycle progression. (A) Depletion of JARID1B results in accumulation of G2/M cells by FACS analysis. H441 cells stably expressing Ctrl shRNA and JARID1B shRNA individually were stained with PI for the analysis of cell cycle distribution. (B) Quantification data for A. ** p < 0.01, t-test. (DOCX 153 kb

Additional file 2: of Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor

Figure S1. Bioinformatics analysis using TCGA database. The comparative box plots between the normal tissue (left plot) and lung cancer tissues (right plot) indicate that a significantly higher expression level of KDM5B and KDM5C is detected in the NSCLC patients, with KDM5B being more prominent. **p < 0.01; ***p < 0.001, t-test. (DOCX 143 kb